SpringerLink
Log in

Chronic Obstructive Pulmonary Disease (COPD)

Risk Factors, Diagnosis and Treatment

  • Chapter
  • First Online:
Airway diseases

  • 92 Accesses

Abstract

Chronic obstructive pulmonary disease (COPD) is defined as a nonhomogeneous lung condition with chronic pulmonary symptoms due to abnormalities of the airways and/or alveoli that cause persistent, generally progressive airflow obstruction [1].

Information about diagnosis, staging, and treatment in this chapter has been prepared in the light of current guidelines. For the staging and treatment of the disease, the GOLD 2022 guideline, which is applied in many parts of the world, has been used.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2023. http://goldcopd.org/gold-2023-global-strategy-diagnosis-management-prevention-copd/. Accessed 30 Dec 2022.

  2. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. www.nice.org.uk/guidance/ng115

  3. American Lung Association Epidemiology and Statistics Unit. Trends in COPD (chronic bronchitis and emphysema): morbidity and mortality. 2013. https://www.lung.org/assets/documents/research/copd-trend-report.pdf. Accessed 14 Oct 2019.

  4. World Health Organization. Evidence-informed policy network: EVIPnet in action. 2019. http://www.who.int/evidence. Accessed 6 July 2020.

  5. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005;366(9500):1875–81.

    Article  PubMed  Google Scholar 

  6. Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest. 2011;139(4):752–63.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Global Burden of Disease Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–96.

    Article  Google Scholar 

  8. European Lung. Foundation.org. Accessed 31 Aug.

  9. World Health Organization. Projections of mortality and causes of death, 2016 and 2060, online information available here. https://colinmathers.com/2022/05/10/projections-of-global-deaths-from-2016-to-2060/. Accessed Oct 2022.

  10. Viinanen A, Lassenius MI, Toppila I, Karlsson A, Veijalainen L, Heikkilä JJ, et al. The burden of chronic obstructive pulmonary disease (COPD) in Finland: impact of disease severity and eosinophil count on healthcare resource utilization. Int J Chron Obstruct Pulmon Dis. 2019;14:2409–21.

    Article  PubMed  PubMed Central  Google Scholar 

  11. European Respiratory Society on behalf of the Forum of International Respiratory Societies (FIRS). The global impact of respiratory disease. 3rd ed; 2021. https://www.who.int/gard/publications/The_Global_Impact_of_Respiratory_Disease.pdf. Accessed Oct 2022

    Google Scholar 

  12. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235–45.

    PubMed  PubMed Central  Google Scholar 

  13. Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990–2010: burden of diseases, injuries and risk factors. JAMA. 2013;310(6):591–608.

    Article  CAS  PubMed  Google Scholar 

  14. Agusti A, Melen E, DeMeo DL, Breyer-Kohansal R, Faner R. Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan. Lancet Respir Med. 2022;10(5):512–24.

    Article  CAS  PubMed  Google Scholar 

  15. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet. 2006;367(9518):1216–9.

    Article  PubMed  Google Scholar 

  16. Barnes PJ, Burney PGJ, Silverman EK, Celli BR, Vestbo J, Wedzicha JA. Chronic obstructive pulmonary disease. Macmillan Publishers Limited; 2015. www.nature.com/nrdp

    Google Scholar 

  17. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005;365(9478):2225–36.

    Article  CAS  PubMed  Google Scholar 

  18. Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009;360:2749–57.

    Article  CAS  PubMed  Google Scholar 

  19. Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med. 2009;361:2599–608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ding Z, Wang K, Li J, Tan Q, Tan W, Guo G. Association between glutathione S-transferase gene M1 and T1 polymorphisms and chronic obstructive pulmonary disease risk: a meta-analysis. Clin Genet. 2019;95(1):53–62.

    Article  CAS  PubMed  Google Scholar 

  21. Mercado N, Ito K, Barnes PJ. Accelerated ageing of the lung in COPD: new concepts. Thorax. 2015;70(5):482–9.

    Article  PubMed  Google Scholar 

  22. Cordoba-Lanus E, Cazorla-Rivero S, Garcia-Bello MA, et al. Telomere length dynamics over 10-years and related outcomes in patients with COPD. Respir Res. 2021;22(1):56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bush A. Lung development and aging. Ann Am Thorac Soc. Dec 2016;13(Supplement 5):S438–46.

    Article  PubMed  Google Scholar 

  24. Barker DJ, Godfrey KM, Fall C, et al. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ. 1991;303:671–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Agusti A, Noell G, Brugada J, Faner R. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir Med. 2017;5:935–45.

    Article  PubMed  Google Scholar 

  26. Lange P, Celli B, Agusti A, Jensen GB, Divo M, Faner R, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med. 2015;373:111–22.

    Article  CAS  PubMed  Google Scholar 

  27. Han MK, Agusti A, Celli BR, et al. From GOLD 0 to pre-COPD. Am J Respir Crit Care Med. 2021;203(4):414–23.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Wan ES. The clinical Spectrum of PRISm. Am J Respir Crit Care Med. 2022;206(5):524–5.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Aryal S, Diaz-Guzman E, Mannino DM. Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. Int J Chron Obstruct Pulmon Dis. 2014;9:1145–54.

    PubMed  PubMed Central  Google Scholar 

  30. Tager IB, Ngo L, Hanrahan JP. Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. Am J Respir Crit Care Med. 1995;152:977–83.

    Article  CAS  PubMed  Google Scholar 

  31. De Matteis S, Jarvis D, Darnton A, et al. The occupations at increased risk of COPD: analysis of lifetime job-histories in the population-based UK Biobank Cohort. Eur Respir J. 2019;54(1):1900186.

    Article  PubMed  Google Scholar 

  32. Pathak U, Gupta NC, Suri JC. Risk of COPD due to indoor air pollution from biomass cooking fuel: a systematic review and meta-analysis. Int J Environ Health Res. 2020. https://doi.org/10.1080/09603123.2019.1575951.

  33. Po JY, FitzGerald JM, Carlsten C. Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis. Thorax. 2011;66(3):232–9. https://doi.org/10.1136/thx.2010.147884.

    Article  PubMed  Google Scholar 

  34. Thurston GD, Balmes JR, Garcia E, Gilliland FD, Rice MB, Schikowski T, et al. Outdoor air pollution and new-onset airway disease. An official American Thoracic Society workshop report. Ann Am Thorac Soc. Apr 2020;17(4):387–98.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Pleasants RA, Riley IL, Mannino DM. Defining and targeting health disparities in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016;11:2475–96.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest. 2004;126(1):59–65.

    Article  PubMed  Google Scholar 

  37. de Marco R, Accordini S, Marcon A, et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med. 2011;183(7):891–7.

    Article  PubMed  Google Scholar 

  38. Savran O, Ulrik CS. Early life insults as determinants of chronic obstructive pulmonary disease in adult life. Int J COPD. 2018;13:683–93.

    Article  CAS  Google Scholar 

  39. Hayden LP, Hobbs BD, Cohen RT, et al. Childhood pneumonia increases risk for chronic obstructive pulmonary disease: the COPDGene study. Respir Res. 2015;16:115.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153(5):1530–5.

    Article  CAS  PubMed  Google Scholar 

  41. Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2022;400(10356):921–72.

    Article  PubMed  Google Scholar 

  42. Caramori G, Casolari P, Barczyk A, Durham AL, Stefano AD, Adcock I. COPD immunopathology. Semin Immunopathol. 2016;38:497–515. https://doi.org/10.1007/s00281-016-0561-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Anzueto A, Miravitlles M. Pathophysiology of dyspnea in COPD. Postgrad Med. 2017;129(3):366–74.

    Article  PubMed  Google Scholar 

  44. Lansing RW, Gracely RH, Banzett RB. The multiple dimensions of dyspnea: review and hypotheses. Respir Physiol Neurobiol. 2009;167:53–60.

    Article  PubMed  Google Scholar 

  45. Binks AP, Moosavi SH, Banzett RB, et al. “Tightness” sensation of asthma does not arise from the work of breathing. Am J Respir Crit Care Med. 2002;165:78–82.

    Article  PubMed  Google Scholar 

  46. Miravitlles M, Worth H, Soler Cataluña JJ, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15:122.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lange P, Marott JL, Vestbo J, et al. Prevalence of night-time dyspnoea in COPD and its implications for prognosis. Eur Respir J. 2014;43:1590–8.

    Article  PubMed  Google Scholar 

  48. Miravitlles M, Anzueto A, Legnani D, Forstmeier L, Fargel M. Patient’s perception of exacerbations of COPD – the PERCEIVE study. Respir Med. 2007;101:453–60.

    Article  PubMed  Google Scholar 

  49. Cerveri I, Accordini S, Corsico A, et al. Chronic cough and phlegm in young adults. Eur Respir J. 2003;22:413–7.

    Article  CAS  PubMed  Google Scholar 

  50. Vestbo J, Rasmussen FV. Respiratory symptoms and FEV1 as predictors of hospitalization and medication in the following 12 years due to respiratory disease. Eur Respir J. 1989;2:710–5.

    Article  CAS  PubMed  Google Scholar 

  51. Smith J, Woodcock A. Cough and its importance in COPD. Int J COPD. 2006;1(3):305–14.

    Article  Google Scholar 

  52. Ramos FL, Krahnke JS, Kim V. Clinical issues of mucus accumulation in COPD. Int J COPD. 2014;9:139–50.

    Google Scholar 

  53. De Marco R, Accordini S, Cerveri I, et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med. 2007;175:32–9.

    Article  PubMed  Google Scholar 

  54. Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airways pathology. Am J Respir Crit Care Med. 2007;176:454–9.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196–204.

    Article  CAS  PubMed  Google Scholar 

  56. Dornhorst AC. Respiratory insufficiency. Lancet. 1955 June 11;268(6876):1185–7. [PubMed] [Google Scholar].

    Google Scholar 

  57. O’Neill S, McCarthy DS. Postural relief of dyspnoea in severe chronic airflow limitation: relationship to respiratory muscle strength. Thorax. 1983;38:595–600.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Anderson CL, Shankar PS, Scott JH. Physiological significance of sternomastoid muscle contraction in chronic obstructive pulmonary disease. Respir Care. 1980;25:937–9.

    Google Scholar 

  59. Sarkar M, Bhardwaz R, Madabhavi I, Modi M. Physical signs in patients with chronic obstructive pulmonary disease. Lung India. 2019;36:38–47.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Garcia-Pachon E, Padilla-Navas I. Frequency of Hoover’s sign in stable patients with chronic obstructive pulmonary disease. Int J Clin Pract. 2006;60(5):514–7. https://doi.org/10.1111/j.1368-5031.2006.00850.x.

    Article  CAS  PubMed  Google Scholar 

  61. Fletcher CM. The clinical diagnosis of pulmonary emphysema; an experimental study. Proc R Soc Med. 1952;45:577–84.

    CAS  PubMed  Google Scholar 

  62. Oshaug K, Halvorsen PA, Melbye H. Should chest examination be reinstated in the early diagnosis of chronic obstructive pulmonary disease? Int J Chron Obstruct Pulmon Dis. 2013;8:369–77.

    PubMed  PubMed Central  Google Scholar 

  63. Glover R, Cooper BG, Llyod J. Forced expiratory time (FET) as an indicator for airways obstruction. Eur Respir J. 2014;44:1819.

    Google Scholar 

  64. Aggarwal AN, Das S, Agarwal R, Singh N. Utility of forced expiratory time as a screening tool for identifying airway obstruction and systematic review of English literature. Lung India. 2018;35:476–82.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2004;117(Suppl 12A):24S–32S.

    CAS  PubMed  Google Scholar 

  66. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;7(7):CD009285.

    Google Scholar 

  67. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–103.

    Article  CAS  PubMed  Google Scholar 

  68. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54.

    Article  CAS  PubMed  Google Scholar 

  69. Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71:15–25.

    Article  PubMed  Google Scholar 

  70. Zacarias EC, Castro AA, Cendon S. Effect of theophylline associated with short-acting or long-acting inhaled beta2-agonists in patients with stable chronic obstructive pulmonary disease: a systematic review. J Bras Pneumol. 2007;33(2):152–60.

    Article  PubMed  Google Scholar 

  71. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9(9):CD006829.

    Google Scholar 

  72. Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;8(8):CD006826.

    Google Scholar 

  73. Agusti A, Fabri LM, Singh D, Vestbo J, Celli B, Franssen FME, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J. 2018;52:1801219. https://doi.org/10.1183/13993003.01219-2018.

    Article  CAS  PubMed  Google Scholar 

  74. Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–56. https://doi.org/10.1016/S2213-2600(19)30190-0. Epub 2019 July 4

    Article  CAS  PubMed  Google Scholar 

  75. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6:117–26.

    Article  CAS  PubMed  Google Scholar 

  76. Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029–36.

    Article  PubMed  Google Scholar 

  77. Crim C, Calverley PMA, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34:641–7.

    Article  CAS  PubMed  Google Scholar 

  78. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210–23.

    Article  CAS  PubMed  Google Scholar 

  79. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–94.

    Article  PubMed  Google Scholar 

  80. Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–8.

    Article  PubMed  Google Scholar 

  81. Wedzicha JA, Calverley PMA, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int J COPD. 2016;11:81–90.

    Article  CAS  Google Scholar 

  82. Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta- analysis. Eur Respir Rev. 2015;24(137):451–61.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG. Impact of erdosteine on chronic bronchitis and COPD: a meta-analysis. Pulm Pharmacol Ther. 2018;48:185–94.

    Article  CAS  PubMed  Google Scholar 

  84. Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–46. https://doi.org/10.1164/rccm.201703-0449OC.

    Article  CAS  PubMed  Google Scholar 

  85. Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–84. https://doi.org/10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9

    Article  CAS  PubMed  Google Scholar 

  86. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35–48. https://doi.org/10.1056/NEJMoa1916046.

    Article  CAS  PubMed  Google Scholar 

  87. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–80. https://doi.org/10.1056/NEJMoa1713901. Epub 2018 Apr 18

    Article  CAS  PubMed  Google Scholar 

  88. Wells AD, Woods A, Hilleman DE, Malesker MA. Alpha-1 antitrypsin replacement in patients with COPD. P T. P&T®. July/Aug 2019;44(7):412–5.

    Google Scholar 

  89. Sandhaus R, Turino G, Brantly M. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016;3(3):668–82.

    PubMed  PubMed Central  Google Scholar 

  90. Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, et al. Pharmacologic management of chronic obstructive pulmonary disease an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–69.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Zheng Y, Zhu J, Liu Y, Lai W, Lin C, Qiu K, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ. 2018;363:k4388. https://doi.org/10.1136/bmj.k4388.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Tønnesen C. Smoking cessation and COPD. Eur Respir Rev. 2013;22(127):37–43. https://doi.org/10.1183/09059180.00007212.

  93. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest. 2011;139:591–9.

    Article  CAS  PubMed  Google Scholar 

  94. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;4:CD006103.

    Google Scholar 

  95. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 1999;130:397–403.

    Article  CAS  PubMed  Google Scholar 

  96. Garrastazu R, Garcia-Rivero JL, Ruiz M, Helguera JM, Arenal S, Bonnardeux C, Leon C, Llorca J, Santibanez M. Prevalence of influenza vaccination in chronic obstructive pulmonary disease patients and impact on the risk of severe exacerbations. Arch Bronconeumol. 2016;52:88–95.

    Article  PubMed  Google Scholar 

  97. Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;1:CD001390.

    PubMed  Google Scholar 

  98. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–64.

    Article  PubMed  Google Scholar 

  99. Hill NS. Pulmonary rehabilitation. Proc Am Thorac Soc. 2006;3(1):66–74.

    Article  PubMed  Google Scholar 

  100. Ngaage DL, Hasney K, Cowen ME. The functional impact of an individualized, graded, outpatient pulmonary rehabilitation in end-stage chronic obstructive pulmonary disease. Heart Lung. 2004;33(6):381–9.

    Article  PubMed  Google Scholar 

  101. Garrod R, Marshall J, Barley E, Jones PW. Predictors of success and failure in pulmonary rehabilitation. Eur Respir J. 2006;27(4):788–94.

    Article  CAS  PubMed  Google Scholar 

  102. Ryrso CK, Godtfredsen NS, Kofod LM, et al. Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis. BMC Pulm Med. 2018;18(1):154.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Lindenauer PK, Stefan MS, Pekow PS, et al. Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among medicare beneficiaries. JAMA. 2020;323(18):1813–23.

    Article  PubMed  Google Scholar 

  104. Murphy PB, Rehal S, Arbane G, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA. 2017;317(21):2177–86.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Gordon M, Duffy S, Criner GJ. Lung volume reduction surgery or bronchoscopic lung volume reduction: is there an algorithm for allocation? J Thorac Dis. 2018;10(Suppl 23):S2816–23.

    Article  PubMed  PubMed Central  Google Scholar 

  106. ISHLT: The International Society for Heart & Lung Transplantation [Internet]. Slide sets-overall lung transplantation statistics. Available from: https://ishltregistries.org/registries/slides.asp. Accessed 14 Oct 2019.

  107. Klooster K, ten Hacken NH, Hartman JE, Kerstjens HA, van Rikxoort EM, Slebos DJ. Endobronchial valves for emphysema without interlobar collateral ventilation. N Engl J Med. 2015;373(24):2325–35.

    Article  CAS  PubMed  Google Scholar 

  108. Dursunoğlu N, Köktürk N, Baha A, Bı̇lge AK, Börekçı̇ Ş, Çı̇ftçı̇ F. Comorbidities and their impact on chronic obstructive pulmonary disease. Tuberk Toraks. 2016;64(4):289–98.

    Article  PubMed  Google Scholar 

  109. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassou G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26:586–93.

    Article  CAS  PubMed  Google Scholar 

  110. Wells CE, Baker EH. Metabolic syndrome and diabetes mellitus in COPD. Eur Respir Monogr. 2013;59:117–34.

    Google Scholar 

  111. Janssens W, Lehouck A, Carremans C, Bouillon R, Mathieu C, Decramer M. Vitamin D beyond bones in chronic obstructive pulmonary disease. Time to act. Am J Respir Crit Care Med. 2009;179:630–6.

    Article  CAS  PubMed  Google Scholar 

  112. Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:871–88.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Collop N. Sleep and sleep disorders in chronic obstructive pulmonary disease. Respiration. 2010;80:78–86.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pulmonology, Girne American University, Mersin, Türkiye

    Ayse Baha

  2. Department of Pulmonology, Girne Doctor Akcicek State Hospital, Mersin, Türkiye

    Ayse Baha

  3. Faculty of Medicine, Department of Pulmonary Medicine, Baskent University, Ankara, Turkey

    Aycan Yüksel

  4. Faculty of Medicine, Department of Pulmonary Medicine, Gazi University, Ankara, Turkey

    Nurdan Kokturk

  5. Emeritus Professor of Respiratory Medicine, Institute for Infection and Immunology, St George’s, University of London, London, UK

    Paul Jones

Authors
  1. Ayse Baha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aycan Yüksel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nurdan Kokturk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Otorhinolaryngology, Eskişehir Osmangazi University, Eskisehir, Türkiye

    Cemal Cingi

  2. Department of Pulmonology, Celal Bayar University, Manisa, Türkiye

    Arzu Yorgancıoğlu

  3. Department of Otorhinolaryngology, Kırıkkale University, Kırıkkale, Türkiye

    Nuray Bayar Muluk

  4. Federal University of Bahia School of Medicine and ProAR Foundation, Salvador - Bahia, Brazil

    Alvaro A. Cruz

Section Editor information

  1. Department of Pulmonology, Gazi University School of Medicine, Ankara, Turkey

    I. K. Oguzulgen MD

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Baha, A., Yüksel, A., Kokturk, N., Jones, P. (2023). Chronic Obstructive Pulmonary Disease (COPD). In: Cingi, C., Yorgancıoğlu, A., Bayar Muluk, N., Cruz, A.A. (eds) Airway diseases. Springer, Cham. https://doi.org/10.1007/978-3-031-22483-6_84-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-22483-6_84-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-22482-9

  • Online ISBN: 978-3-031-22483-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation